Menopausal hormone therapy: lower fracture risk, but at a cost?

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1409, 2012-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-TNF therapy: which variables affect cost?

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Anti-TNF therapy: which variables affect cost?

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 546, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Hormone Therapy for the Prevention of Bone Loss in Menopausal Women with Osteopenia: Is it a Viable Option?

By Hohenhaus Mary H.

Drugs, Vol. 67, Iss. 16, 2007-01 ,pp. : 2311-2321

Adis International

Access to resources Recommend Favorite

Androgen deprivation therapy and fracture: the risk dispelled?

Reactions Weekly, Vol. 1, Iss. 1343, 2011-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

n-3 PUFA post-MI: worth the cost?

Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite